毕得医药：2025年半年度净利润约7341万元，同比增加41.6%

Core Viewpoint - Bid Pharma reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the pharmaceutical sector [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 628 million yuan, representing a year-on-year increase of 17.91% [2] - The net profit attributable to shareholders was around 73.41 million yuan, showing a year-on-year increase of 41.6% [2] - Basic earnings per share reached 0.84 yuan, which is a 44.83% increase compared to the previous year [2]